Clinical Trials in New York State

Showing 2821-2840 of 14,718 trials

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT03172754

This is a Phase I/II, open-label, multi-center study of axitinib in combination with nivolumab in patients with previously treated and untreated advanced RCC. This clinical study will be composed of a dose finding phase (Phase I) and two parallel dose expansion phases (Phase II). The dose finding phase will assess the safety of the combination and establish a recommended phase II dose (RP2D, the highest tested dose that is declared safe and tolerable by the Investigators and the Sponsor Investigator) in patients with advanced RCC who have received prior systemic therapy for metastatic disease. Phase II will evaluate the efficacy of the combination at the RP2D in two parallel expansion cohorts in both previously treated and treatment naïve patients.

Renal Cell Carcinoma

Fox Chase Cancer Center98 participantsStarted Jun 2017

Baltimore, Maryland, United States • Albany, New York, United States • New York, New York, United States +1 more locations

Active Not RecruitingPhase 279 miles

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Neovascular Age-Related Macular Degeneration (nAMD)

Kyowa Kirin Co., Ltd.180 participantsStarted Jan 2024

Mesa, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +81 more locations

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Find Trials by Condition in New York State

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

OCS Heart Perfusion Post-Approval Registry

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Clinical Validation Study of the Eximis CS (Contained Segmentation) System

MDR - Comprehensive Primary/Micro Stem & Versa-Dial Ti Humeral Head

Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD

Metabolomics of Obstructive Sleep Apnea

Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women

The CALERIE™ Legacy Study

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)